What is Yecuris?
Yecuris Corporation operates at the intersection of advanced biotechnology and preclinical research services. The company is best known for its FRG platform, which provides researchers with liver-humanized mice that offer unprecedented physiological relevance. This technology is instrumental for organizations engaged in gene editing, gene therapy, and the study of infectious diseases. By streamlining the validation process for innovative therapies, Yecuris addresses critical bottlenecks in the development of treatments for conditions such as NASH, NAFLD, and viral hepatitis. Their decade-long track record has established them as a foundational partner for pharmaceutical firms seeking to reduce discovery timelines and improve the accuracy of preclinical data.
How much funding has Yecuris raised?
Yecuris has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Yecuris
PPP
Public-Private Partnership
What's next for Yecuris?
With this late-stage financing, Yecuris is well-positioned to scale its operational capacity and expand the reach of its FRG platform. The strategic deployment of this capital will likely focus on enhancing the throughput of their research services and deepening their involvement in high-growth therapeutic areas like gene therapy. As the demand for more accurate humanized models grows, Yecuris is expected to leverage its established infrastructure to capture a larger share of the preclinical services market, potentially accelerating the transition of novel therapies from the laboratory to clinical trials.
See full Yecuris company page
